New Results
ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
View ORCID ProfileKoen Vandyck, Rana Abdelnabi, Kusum Gupta, Dirk Jochmans, Andreas Jekle, Jerome Deval, Dinah Misner, Dorothée Bardiot, Caroline S. Foo, Cheng Liu, Suping Ren, Leonid Beigelman, Lawrence M. Blatt, Sandro Boland, Laura Vangeel, Steven Dejonghe, Patrick Chaltin, Arnaud Marchand, Vladimir Serebryany, Antitsa Stoycheva, Sushmita Chanda, Julian A. Symons, Pierre Raboisson, Johan Neyts
doi: https://doi.org/10.1101/2021.02.14.431129
Koen Vandyck
1Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium
Rana Abdelnabi
4Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
Kusum Gupta
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Dirk Jochmans
4Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
Andreas Jekle
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Jerome Deval
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Dinah Misner
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Dorothée Bardiot
5CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium
Caroline S. Foo
4Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
Cheng Liu
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Suping Ren
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Leonid Beigelman
1Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Lawrence M. Blatt
1Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Sandro Boland
5CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium
Laura Vangeel
4Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
Steven Dejonghe
4Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
Patrick Chaltin
3Centre for Drug Design and Discovery (CD3), KU Leuven, Gaston Geenslaan 2, 3001 Leuven, Belgium
5CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium
Arnaud Marchand
5CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium
Vladimir Serebryany
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Antitsa Stoycheva
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Sushmita Chanda
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Julian A. Symons
2Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA
Pierre Raboisson
1Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium
Johan Neyts
4Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
Article usage
Posted February 15, 2021.
ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
Koen Vandyck, Rana Abdelnabi, Kusum Gupta, Dirk Jochmans, Andreas Jekle, Jerome Deval, Dinah Misner, Dorothée Bardiot, Caroline S. Foo, Cheng Liu, Suping Ren, Leonid Beigelman, Lawrence M. Blatt, Sandro Boland, Laura Vangeel, Steven Dejonghe, Patrick Chaltin, Arnaud Marchand, Vladimir Serebryany, Antitsa Stoycheva, Sushmita Chanda, Julian A. Symons, Pierre Raboisson, Johan Neyts
bioRxiv 2021.02.14.431129; doi: https://doi.org/10.1101/2021.02.14.431129
ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
Koen Vandyck, Rana Abdelnabi, Kusum Gupta, Dirk Jochmans, Andreas Jekle, Jerome Deval, Dinah Misner, Dorothée Bardiot, Caroline S. Foo, Cheng Liu, Suping Ren, Leonid Beigelman, Lawrence M. Blatt, Sandro Boland, Laura Vangeel, Steven Dejonghe, Patrick Chaltin, Arnaud Marchand, Vladimir Serebryany, Antitsa Stoycheva, Sushmita Chanda, Julian A. Symons, Pierre Raboisson, Johan Neyts
bioRxiv 2021.02.14.431129; doi: https://doi.org/10.1101/2021.02.14.431129
Subject Area
Subject Areas
- Biochemistry (11718)
- Bioengineering (8724)
- Bioinformatics (29132)
- Biophysics (14936)
- Cancer Biology (12051)
- Cell Biology (17360)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14146)
- Epidemiology (2067)
- Evolutionary Biology (18269)
- Genetics (12223)
- Genomics (16768)
- Immunology (11844)
- Microbiology (28016)
- Molecular Biology (11560)
- Neuroscience (60822)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4940)
- Plant Biology (10401)
- Synthetic Biology (2878)
- Systems Biology (7333)
- Zoology (1642)